AstraZeneca’s Alexion halts ALS trial on lack of efficacy

AstraZeneca’s Alexion division will stop developing a treatment for the neurological disorder ALS due to lack of efficacy in a late-stage trial, the British drugmaker said on Friday.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.